

June 15, 2018

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.
Corporate Representative Norio Hamada, Chairman of the Board and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact: Makoto Kawamura, Corporate Officer, General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Launch of
1 Ingredient/ 2 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 1 ingredient/ 2 products of generic drugs today on June 15, 2018 as below.

New products

Class	Product Name	Original Brand Name
Combination medicine of irbesartan(ARB) and amlodipine besilate(CCB)	Iluamix combination Tablets LD / HD "OHARA"	Aimix combination Tablets LD / HD